

TSH-Lowering Effect of Metformin in Type 2 Diabetic Patients

Differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients

CARLO CAPPELLI, MD¹
MARIO ROTONDI, MD²
ILENIA PIROLA, MD¹
BARBARA AGOSTI, MD³
ELENA GANDOSSO, MD¹
UMBERTO VALENTINI, MD³

ELVIRA DE MARTINO, MD¹
ANTONIO CIMINO, MD³
LUCA CHIOVATO, MD²
ENRICO AGABITI-ROSEI, MD¹
MAURIZIO CASTELLANO, MD¹

RESEARCH DESIGN AND

METHODS — A pilot study was conducted with 11 diabetic hypothyroid patients who were on stable L-T4 substitution (average dose $89.8 \pm 11.5 \mu\text{g/day}$) to examine the short- to mid-term (up to 24 weeks) effects of metformin administration. Serum TSH, free T4 (FT4), free T3 (FT3), total T4 (TT4), and total T3 (TT3) were measured at baseline and 6, 24, and 72 h after starting metformin treatment, as well as after 3 and 6 months of therapy.

A second study was performed in a larger cohort of diabetic patients including 29 euthyroid patients on L-T4 substitution (group I), 18 subclinical hypothyroid patients who did not receive L-T4 treatment (group II), and 54 euthyroid patients in whom thyroid disorders had been excluded by a complete thyroid workup based on clinical history, physical examination, measurement of serum FT4, FT3, TSH, Tg-Ab, and TPO-Ab, as well as thyroid ultrasonography (group III). Type 2 diabetes was diagnosed in accordance with American Diabetes Association criteria (9).

All subjects gave their informed consent to the study, which was performed in accordance with the Declaration of Helsinki.

Statistical analysis

Between- and within-group comparisons were performed by an ANOVA general linear model, including repeated-measures analysis (SPSS version 13; SPSS, Evanston, IL). A P value <0.05 was considered statistically significant.

RESULTS

Pilot study

There were no changes of FT4, FT3, TT4, and TT3 observed throughout the study. Overall, a modest reduction of baseline TSH values (from 2.11 ± 0.55 to 1.5 ± 0.36 mIU/l, NS) was observed after 6 months of metformin treatment; however, one patient showed TSH reduction from 0.5 to 0.09 mIU/l and stable values of FT4 (from 13.3 to 12.9 pg/ml), FT3 (from 3.12 to 2.92 pg/ml), TT4 (from

OBJECTIVE — To assess the interplay between metformin treatment and thyroid function in type 2 diabetic patients.

RESEARCH DESIGN AND METHODS — The acute and long-term effects of metformin on thyroid axis hormones were assessed in diabetic patients with primary hypothyroidism who were either untreated or treated with levothyroxine (L-T4), as well as in diabetic patients with normal thyroid function.

RESULTS — No acute changes were found in 11 patients with treated hypothyroidism. After 1 year of metformin administration, a significant thyrotropin (TSH) decrease ($P < 0.001$) was observed in diabetic subjects with hypothyroidism who were either treated ($n = 29$; from 2.37 ± 1.17 to 1.41 ± 1.21 mIU/l) or untreated ($n = 18$; 4.5 ± 0.37 vs. 2.93 ± 1.48) with L-T4, but not in 54 euthyroid subjects. No significant change in free T4 (FT4) was observed in any group.

CONCLUSIONS — Metformin administration influences TSH without change of FT4 in patients with type 2 diabetes and concomitant hypothyroidism. The need for reevaluation of thyroid function in these patients within 6–12 months after starting metformin is indicated.

Diabetes Care 32:1589–1590, 2009

Metformin is a widely used drug for the treatment of type 2 diabetes (1,2). It is commonly regarded as a safe drug in that no clinically relevant pharmacologic interactions have been described when it is prescribed together with the most commonly used drugs, with the exceptions of folate and B12 vitamin (3–5).

Recently it has been reported that metformin is able to interfere with thyroid hormone profile, as shown by a decrease in the serum levels of thyrotropin (TSH) to subnormal levels in hypothyroid patients in sta-

ble levothyroxine (L-T4) treatment (6,7). However, no data are available for untreated hypothyroid patients or for euthyroid diabetic patients.

Given that both metformin treatment and hypothyroidism are frequent occurrences in diabetic patients (8), we aimed to further characterize the interplay between metformin and circulating thyroid function parameters by evaluating thyroid hormone axes in different categories of patients who were started on metformin because of a first diagnosis of diabetes.

From the ¹Internal Medicine and Endocrinology Unit, Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy; the ²Unit of Internal Medicine and Endocrinology, Fondazione Salvatore Maugeri Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Superiore Prevenzione e Sicurezza Lavoro Laboratory for Endocrine Disruptors, University of Pavia, Pavia, Italy; and the ³Diabetic Unit, Spedali Civili di Brescia, Brescia, Italy.

Corresponding author: Carlo Cappelli, cappelli@med.unibs.it.

Received 13 February 2009 and accepted 30 May 2009.

Published ahead of print at <http://care.diabetesjournals.org> on 5 June 2009. DOI: 10.2337/dc09-0273.

© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Table 1—Demographic, drug treatment, and thyroid function data in the three groups of diabetic subjects

	Group I	Group II	Group III
BMI (kg/m ²)			
Baseline	32.8 ± 5.6	31.2 ± 4.9	33.0 ± 4.9
After 12 months on metformin	32.1 ± 5.7	30.7 ± 4.9	32.7 ± 4.7
TSH (mIU/l)			
Baseline	2.37 ± 1.17	4.52 ± 0.37*	2.74 ± 0.82
After 12 months on metformin	1.41 ± 1.21†	2.93 ± 0.48†	2.56 ± 1.16
FT4 (pg/ml)			
Baseline	12.49 ± 2.09	12.51 ± 2.05	12.82 ± 1.90
After 12 months on metformin	12.63 ± 2.72	12.25 ± 1.82	13.09 ± 2.23

Noncategorical data are means ± SD. Between-group differences: * $P < 0.001$ for group I vs. group III. Within-group differences: † $P < 0.001$ for on treatment vs. baseline.

10.7 to 10.2 $\mu\text{g/dl}$), and TT3 (from 1.07 to 1.04 ng/ml). Withdrawal of metformin in this patient led to an increase of TSH level, which returned to the baseline (pre-metformin) level within 3 months.

Long-term study

Clinical characteristics and most relevant data in the three groups of patients are summarized in Table 1. A significant decrease of TSH levels after 1 year of metformin treatment was observed in group I and group II subjects but not in group III subjects. In detail, mean TSH level was significantly reduced after 1 year on metformin in group I, from 2.37 ± 1.17 mIU/l at baseline to 1.41 ± 1.21 ($P < 0.001$). Furthermore, six patients in this group (20.7%) showed a serum TSH level lower than normal 1 year after starting metformin.

Mean basal TSH level in patients of group II was 4.5 ± 0.37 mIU/l and significantly decreased to 2.93 ± 1.48 after 1 year of metformin ($P < 0.001$); TSH reduction never reached subnormal levels in individual patients of this group. Serum FT4 levels did not significantly change during metformin treatments in any group (Table 1).

CONCLUSIONS— The results of this study showed that 1) the initiation of treatment with metformin was associated with a significant reduction in the serum levels of TSH in diabetic patients with primary hypothyroidism both with L-T4 replacement therapy and untreated; 2) TSH reduction was not associated with reciprocal changes in any other thyroid function parameter; 3) the TSH-lowering effect of metformin developed slowly and was detectable after a few months of treatment; and 4) metformin had no effect on circulating thyroid func-

tion parameters in euthyroid diabetic patients.

These data indicate that the thyroidal repercussion of metformin administration in diabetic patients may be dual: Although no effect is detectable in patients with a normal pituitary-thyroidaxis, significant changes do occur in patients with an underlying thyroid deficiency, both with L-T4 therapy and untreated. This is a clinically relevant observation, especially when considering that hypothyroidism occurs in 10–15% of type 2 diabetic patients (8) and many of them are presumably also treated with metformin.

The mechanism(s) by which metformin lowers TSH level is still unclear, and the design of the present study does not allow drawing causal inferences. However, the present data would exclude biological interferences of metformin with the TSH assay, increased L-T4 absorption from the gastrointestinal tract, or any influence of changes in body weight associated with metformin treatment. We hypothesize that metformin may enhance the inhibitory modulation of thyroid hormones on central TSH secretion. Such an effect would not modify circulating FT3 or TSH levels when the closed-loop control system is normally functioning, but may well explain the reduction of circulating TSH levels observed in subjects with altered thyroid-hypophyseal feedback. Another explanatory hypothesis could be that metformin ameliorates the thyroid function reserve in those patients with hypothyroidism both treated and untreated. Future studies will be needed to fully elucidate the mechanisms of the here-described TSH-lowering effect of metformin.

In conclusion, the results of this study show that metformin administration in di-

abetic patients with hypothyroidism, both with L-T4 therapy and untreated, is associated with a significant reduction in the serum levels of TSH, with no change in FT4. No effect is detectable in patients with an intact pituitary-thyroid axis. A major clinically relevant consequence of our findings is that a reevaluation of thyroid function within 6–12 months after starting metformin seems necessary in diabetic patients with concomitant hypothyroidism.

Acknowledgments— No potential conflicts of interest relevant to this article were reported.

References

1. Bloomgarden ZT. Approaches to treatment of type 2 diabetes. *Diabetes Care* 2008;31:1697–1703
2. Schwartz S, Fonseca V, Berner B, Cramer M, Chiang Y-K, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. *Diabetes Care* 2006;29:759–764
3. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. *Drug Saf* 2005;28:601–631
4. Stocker DJ, Vigersky RA. The effects of metformin and rosiglitazone on vitamin B12, folate and homocysteine in patients with poorly controlled type 2 diabetes (Abstract). Abstract book of the 87th Annual Meeting of The Endocrine Society 2005;Abstract P3-604:693
5. Wulfele MG, Kooy A, Leher P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. *J Intern Med* 2003;254:455–463
6. Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. *J Clin Endocrinol Metab* 2006;91:225–227
7. Isidro ML, Penín MA, Nemiña R, Cordido F. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. *Endocrine* 2007;32:79–82
8. Chubb SA, Davis WA, Inman Z, Davis TM. Prevalence and progression of subclinical hypothyroidism in women with type 2 diabetes: the Fremantle Diabetes Study. *Clin Endocrinol (Oxf)* 2005;62:480–486
9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997;20:1183–1197